CL2023002583A1 - Ligandos peptídicos del receptor 3 de somatostatina restringidos conformacionales y sus conjugados y sus usos. - Google Patents

Ligandos peptídicos del receptor 3 de somatostatina restringidos conformacionales y sus conjugados y sus usos.

Info

Publication number
CL2023002583A1
CL2023002583A1 CL2023002583A CL2023002583A CL2023002583A1 CL 2023002583 A1 CL2023002583 A1 CL 2023002583A1 CL 2023002583 A CL2023002583 A CL 2023002583A CL 2023002583 A CL2023002583 A CL 2023002583A CL 2023002583 A1 CL2023002583 A1 CL 2023002583A1
Authority
CL
Chile
Prior art keywords
somatostatin receptor
conjugates
peptide ligands
conformationally restricted
somatostatin
Prior art date
Application number
CL2023002583A
Other languages
English (en)
Inventor
Afargan Michel
BLUM Eliav
Salitra Yoseph
Original Assignee
Starget Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Starget Pharma Ltd filed Critical Starget Pharma Ltd
Publication of CL2023002583A1 publication Critical patent/CL2023002583A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Las realizaciones de la invención se refieren a péptidos selectivos del receptor de somatostatina para el receptor 3 de somatostatina, métodos para sintetizar análogos de somatostatina y composiciones farmacéuticas y radiofarmacéuticas que comprenden análogos del receptor 3 de somatostatina y métodos para usar tales composiciones para tratamiento y diagnóstico.
CL2023002583A 2021-03-04 2023-08-31 Ligandos peptídicos del receptor 3 de somatostatina restringidos conformacionales y sus conjugados y sus usos. CL2023002583A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163156374P 2021-03-04 2021-03-04

Publications (1)

Publication Number Publication Date
CL2023002583A1 true CL2023002583A1 (es) 2024-01-05

Family

ID=83154927

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002583A CL2023002583A1 (es) 2021-03-04 2023-08-31 Ligandos peptídicos del receptor 3 de somatostatina restringidos conformacionales y sus conjugados y sus usos.

Country Status (9)

Country Link
US (1) US20240165282A1 (es)
EP (1) EP4301392A4 (es)
JP (1) JP2024508880A (es)
CN (1) CN117042789A (es)
AU (1) AU2022228766A1 (es)
CA (1) CA3208792A1 (es)
CL (1) CL2023002583A1 (es)
IL (1) IL305248A (es)
WO (1) WO2022185315A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115583989B (zh) * 2022-12-09 2023-02-28 烟台蓝纳成生物技术有限公司 一种靶向sstr2的化合物及其制备方法和应用
CN118064372B (zh) * 2024-04-24 2024-07-05 四川大学华西医院 卡波西样血管内皮瘤消化液及其用途、消化方法、原代细胞培养方法和原代细胞

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579967B1 (en) * 1999-12-14 2003-06-17 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
CN101883785B (zh) * 2007-12-03 2014-01-15 意大利法尔马科有限公司 新的非选择性生长抑素类似物
PL3166967T3 (pl) * 2014-09-14 2023-07-24 Tel Hashomer Medical Research Infrastructure And Services Ltd. Syntetyczne ligandy receptora somatostatyny

Also Published As

Publication number Publication date
EP4301392A1 (en) 2024-01-10
EP4301392A4 (en) 2024-08-21
IL305248A (en) 2023-10-01
CN117042789A (zh) 2023-11-10
AU2022228766A1 (en) 2023-09-07
JP2024508880A (ja) 2024-02-28
WO2022185315A1 (en) 2022-09-09
US20240165282A1 (en) 2024-05-23
CA3208792A1 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
CL2023002583A1 (es) Ligandos peptídicos del receptor 3 de somatostatina restringidos conformacionales y sus conjugados y sus usos.
CL2019002132A1 (es) Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinético y sus usos.
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
CL2021001430A1 (es) Composiciones de glp-1 y sus usos. (divisional de solicitud 202000422)
UY37695A (es) Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
ES2572260T3 (es) Péptidos útiles en el tratamiento y/o cuidado de la piel y/o membranas mucosas y su uso en composiciones cosméticas o farmacéuticas
PE20190436A1 (es) Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf y un resto de union a pd1
CL2013003634A1 (es) Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
EA201990071A1 (ru) Композиция пептидной вакцины
AR064555A1 (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo
AR069409A1 (es) Variantes de peptidos natriureticos de tipo c
BR112018071466A2 (pt) novos peptídeos de ligação a cd1d imunogênicos
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
DOP2020000082A (es) Administración oral de análogos del péptido glp-1
DOP2021000072A (es) Análogos de proteína tirosina-tirosina y métodos de uso de esta
CL2022001227A1 (es) Agonistas del receptor npy2
CL2017003144A1 (es) Péptidos lipidados resistentes a proteasas
CL2020001846A1 (es) Anticuerpos pac1 y sus usos
CO2023000637A2 (es) Agonistas del receptor npy2 solubles
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
CO2021001290A2 (es) Compuestos peptídicos y usos terapéuticos de los mismos
CL2020002246A1 (es) Expresión de proteína de superficie a neumocócica (pspa)
PE20211772A1 (es) Inmunoterapia con peptidos restringidos a b 08 y una combinacion de peptidos contra el cancer y metodos relacionados